The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with p ...

In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous ...

Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary ...

STARJEMZA ® is a biosimilar to Janssen's Stelara® which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 subunit from binding to the ...

STARJEMZA ® is a biosimilar to Janssen's Stelara® which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 subunit from binding to the ...

(RTTNews) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing ...

GUANGZHOU, China and LONDON, May 27, 2025/ PRNewswire/-- Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma ...